Company profile
Adynxx, Inc.
OTC: ADYX · Healthcare · Biotechnology
#781 of 1,418 Healthcare companies by revenuebottom-decile growth
EA Score
——FH —DQ 46GM —SS 36
v0.1 · 25/100 weight · pillars only
↑ balance-sheet leverage, listing tenure · ↓ market scale, revenue growth (YoY)
Methodology →Revenue TTM
$589.0k
Rev growth YoY (TTM)
-95.1%
Net income (FY)
-$8.4M
Employees
6
as of 2026-08-31
Market cap
$581
as of 2026-08-31
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$2.2M$2.2M2018
Net income-$8.4M-$8.4M2018
Operating income-$5.3M-$5.3M2018
Total assets$9.7M$9.7M2018
Liabilities$1.4M$1.4M2018
Equity$8.3M$8.3M2018
Revenue trend
FY2011 – FY2018 · USD
FY11
FY12
FY13
FY14
FY15
FY16
FY17
FY18
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Adynxx, Inc.’s revenue?
Adynxx, Inc. booked $2.2M in FY2018 revenue, contracting 89% year over year — slower than 90% of Healthcare companies we track, at a -379.8% net margin.
Peers · Healthcare
Perimeter Medical Imaging AI, Inc.39DElicio Therapeutics, Inc.24DFemasys Inc.41DHorizon Space Acquisition II Corp.——Aligos Therapeutics, Inc.48DAmerican Mobile Dental Corp.——Neighbors
San Francisco →Key facts
CEORichard Orr
SectorHealthcare
IndustryBiotechnology
HeadquartersSan Francisco, CA
ExchangeOTC: ADYX
Employees6
IPO date1998-12-18
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.